BTI
VKTX icon

Blue Trust Inc’s Viking Therapeutics VKTX Stock Holding History

Blue Trust Inc’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.7K Sell
482
-330
-41% -$10.6K ﹤0.01% 1714
2025
Q4 		$28.6K Sell
812
-511
-39% -$18.1K ﹤0.01% 1559
2025
Q3 		$34.8K Sell
1,323
-1,153
-47% -$34.4K ﹤0.01% 1524
2025
Q2 		$65.6K Buy
2,476
+529
+27% +$13.9K ﹤0.01% 1245
2025
Q1 		$47K Buy
1,947
+62
+3% +$1.96K ﹤0.01% 1395
2024
Q4 		$75.9K Buy
1,885
+1,478
+363% +$84.3K ﹤0.01% 1052
2024
Q3 		$21.6K Buy
+407
New +$23.9K ﹤0.01% 1914
2023
Q2 		– Sell
-121
Closed -$1K – 2553
2023
Q1 		$1K Hold
121
– – ﹤0.01% 2223
2022
Q4 		$0 Sell
121
-67
-36% -$299 ﹤0.01% 2496
2022
Q3 		$1K Buy
+188
New +$616 ﹤0.01% 2021

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Blue Trust Inc's VKTX Position: Q1 2026 in Review

Blue Trust Inc reduced its Viking Therapeutics (VKTX) stake by 41% in Q1 2026, selling an estimated $10.6K and leaving 482 shares worth $15.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1714.

Blue Trust Inc first reported a position in VKTX in Q3 2022 and has held it in 10 quarters since. The position peaked at $75.9K in Q4 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Blue Trust Inc held 482 shares of Viking Therapeutics worth $15.7K as of Q1 2026.
  • Blue Trust Inc sold 330 Viking Therapeutics shares in Q1 2026, an estimated $10.6K.
  • Viking Therapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q1 2026, its #1714 holding.
  • Blue Trust Inc first reported a position in Viking Therapeutics in Q3 2022 and has held it in 10 quarters since.
  • Blue Trust Inc's Viking Therapeutics position peaked at $75.9K in Q4 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Blue Trust Inc's 13F filing for Q1 2026, filed 20 Apr 2026.